Jenna R Carl1,2, Christopher B Miller1,2,3, Alasdair L Henry1,2,3, Michelle L Davis1,2, Richard Stott1,2,4, Jasper A J Smits5, Richard Emsley6, Jenny Gu1,2,4, Olivia Shin1,2, Michael W Otto7, Michelle G Craske8, Kate E A Saunders4,9, Guy M Goodwin4, Colin A Espie1,2,3. 1. Big Health Inc., San Francisco, California. 2. Big Health Inc., London, UK. 3. Nuffield Department of Clinical Neurosciences, Sleep and Circadian Neuroscience Institute, University of Oxford, Oxford, UK. 4. Department of Psychiatry, University of Oxford, Oxford, UK. 5. Department of Psychology, The University of Texas at Austin, Austin, Texas. 6. Department of Biostatistics and Health Informatics, Institute of Psychiatry, Psychology, & Neuroscience, King's College London, London, UK. 7. Department of Psychological and Brain Sciences, Boston University, Boston, Massachusetts. 8. Anxiety and Depression Research Centre (ADRC), University of California, Los Angeles, California. 9. Oxford Health NHS Foundation Trust, Warneford Hospital, Oxford, UK.
Abstract
BACKGROUND:Cognitive behavioral therapy (CBT) is an efficacious intervention for generalized anxiety disorder (GAD). Digital CBT may provide a scalable means of delivering CBT at a population level. We investigated the efficacy of a novel digital CBT program in those with GAD for outcomes of anxiety, worry, depressive symptoms, sleep difficulty, wellbeing, and participant-specific quality of life. METHODS: This online, two-arm parallel-group superiority randomized controlled trial compared digital CBT with waitlist control in 256 participants with moderate-to-severe symptoms of GAD. Digital CBT (Daylight), was delivered using participants' own smartphones. Online assessments took place at baseline (Week 0; immediately preceding randomization), mid-intervention (Week 3; from randomization), post-intervention (Week 6; primary endpoint), and follow-up (Week 10). RESULTS: Overall, 256 participants were randomized and intention-to-treat analysis found Daylight reduced symptoms of anxiety compared with waitlist control at post-intervention, reflecting a large effect size (adjusted difference [95% CI]: 3.22 [2.14, 4.31], d = 1.08). Significant improvements were found for measures of worry; depressive symptoms, sleep difficulty, wellbeing, and participant-specific quality of life. CONCLUSION:Digital CBT (Daylight) appears to be safe and efficacious for symptoms of anxiety, worry, and further measures of mental health compared with waitlist control in individuals with GAD.
RCT Entities:
BACKGROUND: Cognitive behavioral therapy (CBT) is an efficacious intervention for generalized anxiety disorder (GAD). Digital CBT may provide a scalable means of delivering CBT at a population level. We investigated the efficacy of a novel digital CBT program in those with GAD for outcomes of anxiety, worry, depressive symptoms, sleep difficulty, wellbeing, and participant-specific quality of life. METHODS: This online, two-arm parallel-group superiority randomized controlled trial compared digital CBT with waitlist control in 256 participants with moderate-to-severe symptoms of GAD. Digital CBT (Daylight), was delivered using participants' own smartphones. Online assessments took place at baseline (Week 0; immediately preceding randomization), mid-intervention (Week 3; from randomization), post-intervention (Week 6; primary endpoint), and follow-up (Week 10). RESULTS: Overall, 256 participants were randomized and intention-to-treat analysis found Daylight reduced symptoms of anxiety compared with waitlist control at post-intervention, reflecting a large effect size (adjusted difference [95% CI]: 3.22 [2.14, 4.31], d = 1.08). Significant improvements were found for measures of worry; depressive symptoms, sleep difficulty, wellbeing, and participant-specific quality of life. CONCLUSION: Digital CBT (Daylight) appears to be safe and efficacious for symptoms of anxiety, worry, and further measures of mental health compared with waitlist control in individuals with GAD.
Authors: Alexandra Roy; Elizabeth A Hoge; Pablo Abrante; Susan Druker; Tao Liu; Judson A Brewer Journal: J Med Internet Res Date: 2021-12-02 Impact factor: 5.428
Authors: Eva Szigethy; Aylin Tansel; Alexa N Pavlick; Maria A Marroquin; Catherine D Serio; Valerie Silfee; Meredith L Wallace; Michael J Kingsley; David J Levinthal Journal: Clin Transl Gastroenterol Date: 2021-12-07 Impact factor: 4.488